| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100130 | Journal of Crohn's and Colitis | 2011 | 4 Pages |
Abstract
CyA can be administered orally with good tolerability. We use it as a bridging therapy to Azathioprine. In our population, 84% of those who responded to CyA have not required surgery.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Lisa Sharkey, Fran Bredin, Allison Nightingale, Miles Parkes,